Literature DB >> 15252090

Chiari pelvic osteotomy for advanced osteoarthritis in patients with hip dysplasia.

Hiroshi Ito1, Takeo Matsuno, Akio Minami.   

Abstract

BACKGROUND: It is not clear whether a Chiari pelvic osteotomy performed for the treatment of advanced osteoarthritis can delay the need for total hip arthroplasty. We present the mid-term results of the Chiari pelvic osteotomy performed for the treatment of Tönnis grade-3 osteoarthritis (large cysts, severe narrowing of the joint space, or severe deformity or necrosis of the head with extensive osteophyte formation), with a particular focus on whether this procedure can delay the need for total hip arthroplasty.
METHODS: We followed thirty-two hips in thirty-one patients with Tönnis grade-3 osteoarthritis who had refused total hip arthroplasty and had been treated with a Chiari pelvic osteotomy. The mean age at the time of surgery was 35.2 years. The mean duration of follow-up was 11.2 years, at which time clinical evaluation with the Harris hip score and radiographic evaluation were performed.
RESULTS: The average Harris hip score improved from 52 points preoperatively to 77 points at the time of follow-up; the average pain score improved from 20 to 31 points. Three hips with a hip score of <70 points required total hip arthroplasty. With a hip score of <70 points as the end point, the cumulative rate of survival at ten years was 72%. The clinical outcome was significantly influenced by the preoperative center-edge angle (p = 0.004), the preoperative acetabular head index (p = 0.039), achievement of the appropriate osteotomy level (p = 0.011), and superior migration (p = 0.009) and lateral migration (p = 0.026) of the femoral head.
CONCLUSIONS: Although the clinical results were inferior to those of total hip arthroplasty, Chiari pelvic osteotomy may be an option for young patients with advanced osteoarthritis who prefer a joint-conserving procedure to total hip arthroplasty and accept a clinical outcome that is predicted to be less optimal than that of total hip arthroplasty. Moderate dysplasia and moderate subluxation without complete obliteration of the joint space and a preoperative center-edge angle of at least -10 degrees are desirable selection criteria.

Entities:  

Mesh:

Year:  2004        PMID: 15252090     DOI: 10.2106/00004623-200407000-00011

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

1.  A computer model for evaluating the osteotomy parameters of Chiari pelvic osteotomy.

Authors:  Mohsen Karami; Dariush Gouran Savadkoohi; Ali Ghadirpoor; Sina Rahimpour; Sina Rahimpoor; Mahmood Azghani; Farzam Farahmand
Journal:  Int Orthop       Date:  2009-04-08       Impact factor: 3.075

2.  High survival of dome pelvic osteotomy in patients with early osteoarthritis from hip dysplasia.

Authors:  Takashi Sakai; Takashi Nishii; Masaki Takao; Kenji Ohzono; Nobuhiko Sugano
Journal:  Clin Orthop Relat Res       Date:  2012-02-22       Impact factor: 4.176

3.  Rotational acetabular osteotomy for advanced osteoarthritis of the hip joint with acetabular dysplasia.

Authors:  Masahiko Nozawa; Katsuhiko Maezawa; Keiji Matsuda; Sungon Kim; Katsuo Shitoto; Hisashi Kurosawa
Journal:  Int Orthop       Date:  2008-10-14       Impact factor: 3.075

4.  Triple pelvic osteotomy as treatment for osteoarthritis secondary to developmental dysplasia of the hip.

Authors:  Dirk Janssen; Klaus Kalchschmidt; Bernd-Dietrich Katthagen
Journal:  Int Orthop       Date:  2009-02-12       Impact factor: 3.075

5.  Long-term experience with Chiari's osteotomy.

Authors:  Rainer Kotz; Catharina Chiari; Jochen G Hofstaetter; Andreas Lunzer; Philipp Peloschek
Journal:  Clin Orthop Relat Res       Date:  2009-06-12       Impact factor: 4.176

6.  The results of Chiari pelvic osteotomy in adolescents with a brief literature review.

Authors:  Mohsen Karami; Franck Fitoussi; Brice Ilharreborde; Georges-François Penneçot; Keyvan Mazda; Henri Bensahel
Journal:  J Child Orthop       Date:  2008-01-03       Impact factor: 1.548

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.